Taisho Pharmaceutical Holdings Co., Ltd.
TAISF · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Market Cap | $453 | $443 | $593 | $510 |
| - Cash | $256 | $265 | $250 | $224 |
| + Debt | $3 | $4 | $3 | $3 |
| Enterprise Value | $200 | $181 | $345 | $290 |
| Revenue | $301 | $268 | $282 | $289 |
| % Growth | 12.4% | -4.9% | -2.3% | – |
| Gross Profit | $178 | $164 | $176 | $180 |
| % Margin | 59% | 61.1% | 62.4% | 62.5% |
| EBITDA | $54 | $45 | $45 | $42 |
| % Margin | 18% | 16.6% | 16% | 14.5% |
| Net Income | $19 | $13 | $13 | $20 |
| % Margin | 6.3% | 4.9% | 4.7% | 7% |
| EPS Diluted | 231.42 | 160.93 | 166.63 | 252.44 |
| % Growth | 43.8% | -3.4% | -34% | – |
| Operating Cash Flow | $41 | $29 | $42 | $42 |
| Capital Expenditures | -$50 | -$14 | -$14 | -$9 |
| Free Cash Flow | -$9 | $14 | $28 | $33 |